TMS Co., Ltd.

TMS Co., Ltd. is a Japanese pharmaceutical company founded in 2005 to commercialize drug seeds discovered by Keiji Hasumi, then a professor at Tokyo University of Agriculture and Technology. The company focuses on research and development of drugs targeting soluble epoxide hydrolase (sEH) and other mechanisms, with a pipeline including TMS-007, TMS-008, JX09, and TMS-010. It listed on the Tokyo Stock Exchange Growth Market in November 2022 under ticker 4891.

TMS Co., Ltd. was founded in 2005 to commercialize drug seeds discovered by Keiji Hasumi, a professor at Tokyo University of Agriculture and Technology's Fermentation Science Laboratory. The laboratory traces its research lineage to Dr. Akira Endo, discoverer of statins. In the course of exploring bioactive substances acting on blood coagulation and fibrinolysis, the laboratory discovered many novel compounds, including the SMTP compound group with both thrombolytic and anti-inflammatory effects. In June 2018, TMS signed an option agreement with Biogen for TMS-007, valued at up to $357 million, the largest such deal by a Japanese biotech at the time. In May 2021, Biogen exercised its option for TMS-007. In November 2022, TMS listed on the Tokyo Stock Exchange Growth Market (ticker 4891). In January 2024, Biogen transferred the rights to TMS-007 to JIXING, and TMS signed a strategic partnership agreement with JIXING, acquiring development and sales rights for TMS-007 and JX09 in Japan.

Developing novel and differentiated pharmaceuticals based on unique mechanisms of action, aiming to launch truly breakthrough drugs.

• TMS-007

  SMTP compound with thrombolytic, anti-inflammatory, and antioxidant effects; under clinical development as a treatment for acute cerebral infarction (safety and efficacy confirmed in early Phase II trial).

• TMS-008

  SMTP compound with anti-inflammatory and antioxidant effects; under non-clinical development for acute kidney injury and cancer cachexia.

• JX09

  Being developed by JIXING for treatment-resistant or uncontrolled hypertension; TMS owns development rights in Japan.

• TMS-010

  Under development as a new treatment for spinal cord injury.

1. 1ホーム | 株式会社ティムスtms-japan.co.jp
2. 2沿革 | 企業情報 | 株式会社ティムスtms-japan.co.jp
3. 3コーポレート・ガバナンス | 企業情報 | 株式会社ティムスtms-japan.co.jp
4. 4企業情報 | 株式会社ティムスtms-japan.co.jp
5. 5TMS Co., Ltd. (Japan)wikidata.org